Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides

Inclusion Criteria: * 1\. Male or Female * ≥ 18 years of age * Documentation of diagnosis as evidenced by one or more clinical features consistent with Mycosis Fungoides cutaneous T-Cell lymphoma * Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with requirements of the study * Skin biopsy specimen of representative lesion obtained at screening of study and deemed diagnostic of Mycosis Fungoides by principal investigator * Eligible, in the opinion of the investigator, for low dose TSEBT over the course of two weeks. * Availability of subject to be observed for up to 18 months post-screening evaluation. * Life Expectancy greater than 6 months Exclusion Criteria: * Pregnant or breast-feeding females * Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data * Patients diagnosed with Sezary Syndrome. Sezary Syndrome is equivalent to mycosis fungoides that develops to Stage IVA/B with B2 (high blood tumor burden) involvement, and as such requires a more aggressive treatment regimen than Valchlor or TSEBT. * Patients who do not have their disease downgrade to stage IA or IB 30 days following low dose TSEBT. * Underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to undergo treatment * Minimum 3 weeks since prior systematic treatment or phototherapy * Decisionally-impaired individuals, prisoners, and vulnerable populations